See more : China Sports Industry Group Co., Ltd. (600158.SS) Income Statement Analysis – Financial Results
Complete financial analysis of BioPlus Acquisition Corp. (BIOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPlus Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Sichuan Xichang Electric Power Co.,Ltd. (600505.SS) Income Statement Analysis – Financial Results
- Golden Carpets Limited (GOLCA.BO) Income Statement Analysis – Financial Results
- Yappn Corp. (YPPN) Income Statement Analysis – Financial Results
- New Fortress Energy Inc. (NFE) Income Statement Analysis – Financial Results
- Citrix Systems, Inc. (0HYR.L) Income Statement Analysis – Financial Results
BioPlus Acquisition Corp. (BIOS)
About BioPlus Acquisition Corp.
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 708.90M | 817.20M | 935.60M | 982.20M | 984.10M | 842.20M | 662.60M | 0.00 | 1.64B | 1.33B | 1.40B | 1.20B | 1.15B | 1.07B | 630.50M | 588.80M | 576.60M | 456.60M | 369.80M | 377.40M | 451.10M | 242.30M | 283.20M | 213.90M | 109.30M | 100.00K |
| Cost of Revenue | 1.17M | 0.00 | 465.90M | 547.90M | 670.00M | 721.30M | 723.00M | 570.40M | 437.70M | 0.00 | 1.38B | 1.17B | 1.26B | 1.06B | 1.03B | 957.00M | 562.40M | 520.20M | 506.00M | 403.20M | 334.60M | 347.10M | 421.40M | 239.00M | 278.10M | 213.40M | 106.70M | 0.00 |
| Gross Profit | -1.17M | 0.00 | 243.00M | 269.30M | 265.60M | 260.90M | 261.10M | 271.80M | 224.90M | 0.00 | 260.40M | 157.80M | 142.20M | 137.00M | 119.60M | 116.20M | 68.10M | 68.60M | 70.60M | 53.40M | 35.20M | 30.30M | 29.70M | 3.30M | 5.10M | 500.00K | 2.60M | 100.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 34.28% | 32.95% | 28.39% | 26.56% | 26.53% | 32.27% | 33.94% | 0.00% | 15.89% | 11.87% | 10.14% | 11.44% | 10.38% | 10.83% | 10.80% | 11.65% | 12.24% | 11.70% | 9.52% | 8.03% | 6.58% | 1.36% | 1.80% | 0.23% | 2.38% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.17K | 162.43 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Other Expenses | 1.17M | 0.00 | 189.60M | 220.80M | 197.70M | 465.00M | 35.10M | 40.70M | 13.10M | 4.80M | 27.90M | 1.80M | 96.60M | 2.90M | 6.60M | 36.10M | 3.00M | 1.90M | 500.00K | -200.00K | 1.50M | 7.10M | 4.00M | 0.00 | 26.60M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.17M | 162.43 | 236.90M | 284.10M | 263.70M | 548.60M | 354.50M | 294.70M | 211.60M | 4.80M | 254.20M | 142.40M | 225.70M | 128.20M | 135.80M | 145.40M | 55.80M | 52.50M | 46.40M | 38.30M | 35.40M | 35.10M | 27.10M | 19.10M | 38.20M | 8.00M | 5.30M | 100.00K |
| Cost & Expenses | 1.17M | 162.43 | 702.80M | 832.00M | 933.70M | 1.27B | 1.08B | 865.10M | 649.30M | 4.80M | 1.63B | 1.31B | 1.49B | 1.19B | 1.17B | 1.10B | 618.20M | 572.70M | 552.40M | 441.50M | 370.00M | 382.20M | 448.50M | 258.10M | 316.30M | 221.40M | 112.00M | 100.00K |
| Interest Income | 3.17M | 9.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | -57.40M | -52.10M | -38.20M | -37.30M | -38.50M | 28.20M | 26.07M | 28.31M | -27.60M | -1.90M | -2.70M | -3.30M | -3.00M | -400.00K | -800.00K | -800.00K | -800.00K | -100.00K | 800.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 23.60M | 27.73M | 21.55M | 22.74M | -81.10M | -16.10M | 73.07M | 15.88M | 12.33M | 5.03M | 6.40M | 7.09M | 10.86M | 9.92M | 5.03M | 5.08M | 6.06M | 6.36M | 4.88M | 3.22M | 1.69M | 1.09M | 780.00K | 370.00K | 90.00K | 0.00 |
| EBITDA | -1.17M | 9.49 | -84.90M | -24.97M | -56.15M | -335.76M | -174.60M | -39.00M | 86.37M | 39.39M | -36.67M | 16.63M | -82.50M | 9.39M | -11.44M | -19.98M | 15.73M | 19.48M | 28.66M | 21.36M | 3.98M | 420.00K | 7.69M | -10.11M | -29.62M | -5.73M | -2.21M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -11.98% | -3.06% | -6.00% | -34.18% | -17.74% | -4.63% | 13.03% | 0.00% | -2.24% | 1.25% | -5.88% | 0.78% | -0.99% | -1.86% | 2.49% | 3.31% | 4.97% | 4.68% | 1.08% | 0.11% | 1.70% | -4.17% | -10.46% | -2.68% | -2.02% | 0.00% |
| Operating Income | -1.17M | -162.43 | -108.50M | -52.70M | -77.70M | -358.50M | -93.50M | -22.90M | 13.30M | 23.51M | -49.00M | 11.60M | -88.90M | 2.30M | -22.30M | -29.90M | 10.70M | 14.40M | 22.60M | 15.00M | -900.00K | -2.80M | 6.00M | -11.20M | -30.40M | -6.10M | -2.30M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -15.31% | -6.45% | -8.30% | -36.50% | -9.50% | -2.72% | 2.01% | 0.00% | -2.99% | 0.87% | -6.34% | 0.19% | -1.93% | -2.79% | 1.70% | 2.45% | 3.92% | 3.29% | -0.24% | -0.74% | 1.33% | -4.62% | -10.73% | -2.85% | -2.10% | 0.00% |
| Total Other Income/Expenses | 3.17M | 9.49 | 57.50M | -14.70M | 45.30M | 33.50M | -38.50M | -28.20M | -26.10M | -28.31M | 27.60M | 1.90M | 2.70M | 3.30M | 3.00M | 300.00K | 800.00K | 800.00K | 800.00K | 100.00K | -800.00K | -1.00M | -1.70M | -2.30M | -1.40M | -700.00K | -200.00K | 0.00 |
| Income Before Tax | 2.00M | -152.95 | -51.00M | -67.40M | -32.40M | -325.00M | -132.00M | -51.10M | -12.80M | -4.80M | -21.40M | 13.50M | -86.20M | 5.60M | -19.30M | -29.60M | 11.50M | 15.20M | 23.40M | 15.10M | -1.70M | -3.80M | 4.30M | -13.50M | -31.80M | -6.80M | -2.50M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -7.19% | -8.25% | -3.46% | -33.09% | -13.41% | -6.07% | -1.93% | 0.00% | -1.31% | 1.02% | -6.15% | 0.47% | -1.67% | -2.76% | 1.82% | 2.58% | 4.06% | 3.31% | -0.46% | -1.01% | 0.95% | -5.57% | -11.23% | -3.18% | -2.29% | 0.00% |
| Income Tax Expense | -3.17M | 9.49 | 600.00K | 63.60M | 2.00M | -21.50M | 11.40M | 2.50M | -4.40M | 28.31M | 47.70M | -40.60M | -12.20M | 2.30M | 19.00M | -5.70M | 4.50M | 6.10M | 4.70M | 900.00K | 100.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Net Income | 5.16M | -152.95 | -51.60M | -131.00M | -34.40M | -303.50M | -143.40M | -53.60M | -8.40M | -33.11M | -69.10M | 54.10M | -74.00M | 3.30M | -38.30M | -23.90M | 7.00M | 9.10M | 18.70M | 14.20M | -1.80M | -4.80M | 2.60M | -15.80M | -33.20M | -7.50M | -2.70M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -7.28% | -16.03% | -3.68% | -30.90% | -14.57% | -6.36% | -1.27% | 0.00% | -4.22% | 4.07% | -5.28% | 0.28% | -3.32% | -2.23% | 1.11% | 1.55% | 3.24% | 3.11% | -0.49% | -1.27% | 0.58% | -6.52% | -11.72% | -3.51% | -2.47% | 0.00% |
| EPS | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| EPS Diluted | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| Weighted Avg Shares Out | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
| Weighted Avg Shares Out (Dil) | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against BioScrip, Inc.
WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.: Do you, or did you, own shares of BioScrip, Inc. (NASDAQ GS: BIOS)? Did you purchase your shares before August 8, 2011, or between August 8, 2011 and September 20, 2013, inclusive? Did you...
Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of BioScrip, Inc.
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of shareholders of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS) concerning possible breaches of fiduciary duties by the Company or its fiduciaries. The investigation...
BioScrip to Present at 31ST Annual J.P. Morgan Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference to be held January 7-10, 2013 at the Westin St. Francis in San Francisco, CA. Richard Smith, President and...
BioScrip Enters into Agreement to Acquire HomeChoice Partners, Inc.
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that it has entered into a definitive agreement to acquire HomeChoice Partners, Inc. (“HomeChoice”), a leading provider of alternate-site infusion pharmacy services, for $70.0 million in cash. HomeChoice is a majority-owned subsidiary...
BioScrip to Present at Oppenheimer 23rd Annual Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Oppenheimer 23rd Annual Healthcare Conference to be held December 12-13, 2012 at the Waldorf=Astoria in New York City. Hai Tran, Chief Financial Officer, will present...
BioScrip to Present at Stephens Fall Investment Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Stephens Fall Investment Conference to be held at the New York Palace Hotel in New York City on November 13-14, 2012. Richard M. Smith, President...
BioScrip Reports Third Quarter 2012 Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced 2012 third quarter financial results. Third quarter revenue from continuing operations was $170.4 million and the net loss from continuing operations was $0.6 million, or $0.01 per diluted share. Consolidated Adjusted EBITDA...
BioScrip to Host Third Quarter 2012 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2012 third quarter financial results on Wednesday, November 7, 2012, after the market closes. The Company will host a conference call at 9:00 a.m. Eastern Standard Time...
BioScrip to Present at Morgan Stanley Global Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced that the Company will present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt in New York City on September 10-12, 2012. Hai Tran, Chief Financial Officer,...
BioScrip Reports Second Quarter 2012 Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) today announced 2012 second quarter financial results. Second quarter revenue, from continuing operations, was $155.9 million and net loss, from continuing operations, was $4.3 million, or $0.07 per diluted share. Consolidated Adjusted EBITDA for...
Source: https://incomestatements.info
Category: Stock Reports